SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Borre Michael) "

Sökning: WFRF:(Borre Michael)

  • Resultat 1-10 av 21
  • [1]23Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Dadaev, Tokhir, et al. (författare)
  • Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.
  • 2018
  • Ingår i: ; 9:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Prostate cancer is a polygenic disease with a large heritable component. A number of common, low-penetrance prostate cancer risk loci have been identified through GWAS. Here we apply the Bayesian multivariate variable selection algorithm JAM to fine-map 84 prostate cancer susceptibility loci, using summary data from a large European ancestry meta-analysis. We observe evidence for multiple independent signals at 12 regions and 99 risk signals overall. Only 15 original GWAS tag SNPs remain among the catalogue of candidate variants identified; the remainder are replaced by more likely candidates. Biological annotation of our credible set of variants indicates significant enrichment within promoter and enhancer elements, and transcription factor-binding sites, including AR, ERG and FOXA1. In 40 regions at least one variant is colocalised with an eQTL in prostate cancer tissue. The refined set of candidate variants substantially increase the proportion of familial relative risk explained by these known susceptibility regions, which highlights the importance of fine-mapping studies and has implications for clinical risk profiling.
  •  
2.
  •  
3.
  •  
4.
  • Eriksen, Anne Kirstine, et al. (författare)
  • A lifestyle intervention among elderly men on active surveillance for non-aggressive prostate cancer: a randomised feasibility study with whole-grain rye and exercise.
  • 2017
  • Ingår i: Trials. - : BioMed Central. - 1745-6215. ; 18:1, s. 20-
  • Tidskriftsartikel (refereegranskat)abstract
    • The prognosis for men with non-aggressive prostate cancer is good, and several studies have investigated the impact of lifestyle changes including physical activity and diet on the prognosis. Despite positive results in animal studies and a few human interventions with whole-grain rye on markers of prostate cancer progression, the feasibility of trials investigating such dietary changes in combination with physical activity remains largely unstudied. The primary aim was to investigate the feasibility of an intervention with high whole-grain rye intake and vigorous physical activity for 6 months in men diagnosed with prostate cancer.
  •  
5.
  • Nissen, Eva Rames, et al. (författare)
  • Internet-delivered mindfulness-based cognitive therapy for anxiety and depression in cancer survivors : A randomized controlled trial
  • 2020
  • Ingår i: Psycho-Oncology. - : John Wiley & Sons. - 1057-9249 .- 1099-1611. ; 29:1, s. 68-75
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective Internet-delivered interventions may alleviate distress in cancer survivors with limited access to psychological face-to-face treatment. In collaboration with a group of cancer survivors, we developed and tested the efficacy of a therapist-assisted internet-delivered mindfulness-based cognitive therapy (iMBCT) program for anxiety and depression in cancer survivors. Methods A total of 1282 cancer survivors were screened for anxiety and depression during their routine oncology follow-up; eligible breast (n = 137) and prostate cancer (n = 13) survivors were randomized to iMBCT or care-as-usual (CAU) wait-list. Primary outcomes of anxiety and depression were assessed at baseline, 5 weeks, 10 weeks (post intervention), and 6 months. Results Significant effects were found for both anxiety (Cohen's d = 0.45; P = .017) and depressive symptoms (d = 0.42; P = .024) post intervention. The effects were maintained at follow-up for anxiety (d = 0.40; P = .029), but not for depressive symptoms (d = 0.28; P = .131). Conclusions Our preliminary findings suggest iMBCT to be a helpful intervention for cancer survivors suffering from symptoms of anxiety. Further studies on the efficacy for symptoms of depression are needed.
  •  
6.
  •  
7.
  • Ahlgren, Göran M., et al. (författare)
  • Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer : Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
  • 2018
  • Ingår i: European Urology. - : Elsevier. - 0302-2838. ; 73:6, s. 870-876
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Adjuvant chemotherapy is standard treatment for other solid tumours, but to date has not proven effective in prostate cancer. Objective: o evaluate whether six cycles of docetaxel alone improve biochemical disease-free survival after radical prostatectomy for high-risk prostate cancer. Design, setting, and participants: Open-label, randomised multinational phase 3 trial. Enrolment of 459 patients after prostatectomy. Inclusion criteria: high-risk pT2 margin positive or pT3a Gleason score ≥4+3, pT3b, or lymph node positive disease Gleason score ≥3+4. Patients assigned (1:1) to either six cycles of adjuvant docetaxel 75mg/m2 every 3 wk without daily prednisone (Arm A) or surveillance (Arm B) until endpoint was reached. Primary endpoint was prostate-specific antigen progression ≥0.5 ng/ml. Intervention: Docetaxel treatment after prostatectomy. Results and limitations: Median time to progression, death, or last follow-up was 56.8 mo. Primary endpoint was reached in 190/459 patients-the risk of progression at 5 yr being 41% (45% in Arm A and 38% in Arm B). There was evidence of nonproportional hazards in Kaplan-Meier analysis, so we used the difference in restricted mean survival time as the primary estimate of effect. Restricted mean survival time to endpoint was 43 mo in Arm A versus 46 mo in Arm B (p = 0.06), a nonsignificant difference of 3.2 mo (95% confidence interval: 6.7 to -1.5 mo). A total of 116 serious adverse events were recorded in Arm A and 41 in Arm B with no treatment-related deaths. Not all patients received docetaxel by protocol. The endpoint is biochemical progression and some patients received radiation treatment before the endpoint. Conclusions: Docetaxel without hormonal therapy did not significantly improve biochemical disease-free survival after radical prostatectomy. Patient summary: In this randomised trial, we tested whether chemotherapy after surgery for high-risk prostate cancer decreases the risk of a rising prostate-specific antigen. We found no benefit from docetaxel given after radical prostatectomy. In this randomised trial, docetaxel without hormonal therapy or continuous corticosteroids was given after radical prostatectomy for high-risk prostate cancer. We found no benefit from docetaxel alone given after radical prostatectomy.
  •  
8.
  • Beer, Tomasz M., et al. (författare)
  • Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer : Extended Analysis of the Phase 3 PREVAIL Study
  • Ingår i: European Urology. - : Elsevier. - 0302-2838. ; 71:2, s. 151-154
  • Tidskriftsartikel (refereegranskat)abstract
    • Enzalutamide significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) among men with chemotherapy-naïve metastatic castration-resistant prostate cancer at the prespecified interim analysis of PREVAIL, a phase 3, double-blind, randomized study. We evaluated the longer-term efficacy and safety of enzalutamide up to the prespecified number of deaths in the final analysis, which included an additional 20 mo of follow-up for investigator-assessed rPFS, 9 mo of follow-up for OS, and 4 mo of follow-up for safety. Enzalutamide reduced the risk of radiographic progression or death by 68% (hazard ratio [HR] 0.32, 95% confidence interval [CI] 0.28–0.37; p < 0.0001) and the risk of death by 23% (HR 0.77, 95% CI 0.67–0.88; p = 0.0002). Median investigator-assessed rPFS was 20.0 mo (95% CI 18.9–22.1) in the enzalutamide arm and 5.4 mo (95% CI 4.1–5.6) in the placebo arm. Median OS was 35.3 mo (95% CI 32.2–not yet reached) in the enzalutamide arm and 31.3 mo (95% CI 28.8–34.2) in the placebo arm. At the time of the OS analysis, 167 patients in the placebo arm had crossed over to receive enzalutamide. The most common adverse events in the enzalutamide arm were fatigue, back pain, constipation, and arthralgia. This final analysis of PREVAIL provides more complete assessment of the clinical benefit of enzalutamide. PREVAIL is registered on ClinicalTrials.gov as NCT01212991. Patient summary According to data from longer follow-up, enzalutamide continued to provide benefit over placebo in patients with metastatic castration-resistant prostate cancer.
  •  
9.
  • Bird, Lori, et al. (författare)
  • Wind and solar energy curtailment : A review of international experience
  • 2016
  • Ingår i: Renewable & sustainable energy reviews. - : Elsevier. - 1364-0321 .- 1879-0690. ; 65, s. 577-586
  • Forskningsöversikt (refereegranskat)abstract
    • Greater penetrations of variable renewable generation on some electric grids have resulted in increased levels of curtailment in recent years. Studies of renewable energy grid integration have found that curtailment levels may grow as the penetration of wind and solar energy generation increases. This paper reviews international experience with curtailment of wind and solar energy on bulk power systems in recent years, with a focus on eleven countries in Europe, North America, and Asia. It examines levels of curtailment, the causes of curtailment, curtailment methods and use of market based dispatch, as well as operational, institutional, and other changes that are being made to reduce renewable energy curtailment.
  •  
10.
  • Corbane, Christina, et al. (författare)
  • Remote sensing for mapping natural habitats and their conservation status - New opportunities and challenges
  • Ingår i: International Journal of Applied Earth Observation and Geoinformation. - : Elsevier. - 1569-8432. ; 37, s. 7-16
  • Tidskriftsartikel (refereegranskat)abstract
    • Safeguarding the diversity of natural and semi-natural habitats in Europe is one of the aims set out by the Habitats Directive (Council Directive 92/43/EEC on the conservation of natural habitats and of wild fauna and flora) and one of the targets of the European 2020 Biodiversity Strategy, and is to be accomplished by maintaining a favourable conservation status. To reach this aim a high-level understanding of the distribution and conditions of these habitats is needed. Remote sensing can considerably contribute to habitat mapping and their observation over time. Several European projects and a large number of scientific studies have addressed the issue of mapping and monitoring natural habitats via remote sensing and the deriving of indicators on their conservation status. The multitude of utilized remote sensing sensors and applied methods used in these studies, however, impede a common understanding of what is achievable with current state-of-the-art technologies. The aim of this paper is to provide a synthesis on what is currently feasible in terms of detection and monitoring of natural and semi-natural habitats with remote sensing. To focus this endeavour, we concentrate on those studies aimed at direct mapping of individual habitat types or discriminating between different types of habitats occurring in relatively large, spatially contiguous units. By this we uncover the potential of remote sensing to better understand the distribution of habitats and the assessment of their conservation status in Europe.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 21
  • [1]23Nästa
Typ av publikation
tidskriftsartikel (18)
forskningsöversikt (2)
konferensbidrag (1)
Typ av innehåll
refereegranskat (21)
Författare/redaktör
Sun, Z. (4)
Jenster, G (4)
Castano-Vinyals, G (4)
Kim, J. (4)
Hakansson, N. (4)
Auvinen, A (4)
visa fler...
Khaw, Kay-Tee (4)
Riboli, E. (4)
Key, TJ (4)
Khaw, KT (4)
Brenner, H (4)
SCHAID, DJ (4)
Ma, J (4)
Wolk, A (4)
Wolk, Alicja (4)
Donovan, Jenny L (4)
Hamdy, Freddie C (4)
Neal, David E (4)
Eeles, Rosalind A (4)
Haiman, Christopher ... (4)
Kote-Jarai, Zsofia (4)
Schumacher, Fredrick ... (4)
Benlloch, Sara (4)
Muir, Kenneth (4)
Berndt, Sonja I (4)
Conti, David V (4)
Wiklund, Fredrik (4)
Gapstur, Susan M (4)
Stevens, Victoria L (4)
Tangen, Catherine M (4)
Batra, Jyotsna (4)
Pashayan, Nora (4)
Schleutker, Johanna (4)
Albanes, Demetrius (4)
Cancel-Tassin, Geral ... (4)
Koutros, Stella (4)
Maehle, Lovise (4)
Travis, Ruth C (4)
Lu, Yong-Jie (4)
Giles, Graham G (4)
Kibel, Adam S (4)
Vega, Ana (4)
Kogevinas, Manolis (4)
Penney, Kathryn L (4)
Park, Jong Y (4)
Stanford, Janet L (4)
Cybulski, Cezary (4)
Brenner, Hermann (4)
Maier, Christiane (4)
Kim, Jeri (4)
visa färre...
Lärosäte
Lunds universitet (9)
Uppsala universitet (7)
Karolinska Institutet (5)
Umeå universitet (2)
Kungliga Tekniska Högskolan (1)
Chalmers tekniska högskola (1)
visa fler...
Linnéuniversitetet (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (21)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (11)
Teknik (2)
Lantbruksvetenskap (2)
Samhällsvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy